$ACHV low debt, funded through Q4 and possibly longer if warrants convert, low burn rate, very solid P2 results, Chantix coming off patent, decades of safe cytisinicline use in Europe, 2 upcoming catalysts shortly (submission of additional safety data due Q1 with start of P3 soon thereafter-expecting rapid enrollment-and P3 completion/readout around fall) offering at .60, some decent tute ownership, insider options at .60, non dilututive funds being pursued to now address vaping, nice gap down on good news to shake out those chatroom pumpers, yes please, more lower please!
  • 5
  • 19